BioGenCell

About:

BioGenCell designs cellular therapies that treat blood flow problems in the limbs, a side effect of diabetes and heart disease.

Website: http://www.biogencell.net/

Top Investors: Marius Nacht

Description:

BioGenCell designs cellular therapies that treat blood flow problems in the limbs, a side effect of diabetes and heart disease. Its technology creates autologous cells, derived from the patients themselves, to repair themselves. Its lead product, BC1, uses the company's technology to treat blood vessel insufficiency that can cause multiple organ failure in diabetic patients. Derived from the patient's own adult stem cells, its easy-to-use and cost-effective therapies can regenerate damaged tissues, with the eventual goal of treating a wide range of degenerative diseases including diabetes, heart failure, stroke, blindness, cancer, and immunological diseases. Its patented technology platform provides a comprehensive solution for most aspects of cellular therapy and supports rapid manufacturing and long-term storage (bio-banking) of therapeutic cellular products for use in patient treatment.

Total Funding Amount:

$16M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Netanya, HaMerkaz, Israel

Founded Date:

2008-01-01

Contact Email:

debbie.mahfud(AT)biogencell.net

Founders:

Eyal Peleg

Number of Employees:

1-10

Last Funding Date:

2022-05-09

IPO Status:

Private

Industries:

© 2025 bioDAO.ai